The utility of a model-based cost-effectiveness analysis of degarelix versus leuprolide in the therapy of hormone-dependent advanced prostate cancer. FE [Internet]. 2013 Sep. 11 [cited 2025 Oct. 29];14(3):131-46. Available from: https://journals.seedstm.com/index.php/FE/article/view/700